Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

被引：0
|
作者：
Chari, Ajai [1 ]
Dimopoulos, Meletios-Athanasios [2 ]
Beksac, Meral [3 ]
Leleu, Xavier [4 ,5 ]
Weisel, Katja [6 ]
Richter, Joshua [7 ]
Dirnberger, Franziska [8 ]
Iskander, Karim [8 ]
Yusuf, Akeem [8 ]
Mikhael, Joseph [9 ]
机构：
[1] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Gen Hosp, Athens, Greece
[3] Ankara Univ, Ankara, Turkey
[4] CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France
[5] CIC Inserm 1402, Poitiers, France
[6] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany
[7] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA
[8] Amgen Inc, Thousand Oaks, CA 91320 USA
[9] City Hope Canc Ctr, Translat Genom Res Inst TGen, Duarte, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-191
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [41] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [42] Indirect Comparisons to Assess the Relative Efficacy of Carfilzomib plus Lenalidomide plus Dexamethasone Versus Panobinostat plus Bortezomib plus Dexamethasone and Bortezomib plus Dexamethasone: A Matching Adjusted Indirect Comparison
    Rael, Michael
    Benedict, Agnes
    Ishak, Jack
    Cadarette, Sarah
    Campioni, Marco
    Panjabi, Sumeet
    BLOOD, 2015, 126 (23)
  • [43] Health-Related Quality of Life With Pomalidomide plus Dexamethasone plus Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients
    Reece, Donna
    Bahlis, Nizar J.
    Samaras, Christy Joy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Agarwal, Amit
    Chung, Weiyuan
    Zafar, Faiza
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E277 - E278
  • [44] Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience
    Magee, Gray
    Mansour, Razan
    Chang, Mark
    Atrash, Shebli
    Ahmed, Nausheen
    Mushtaq, Muhammad Umair
    Ouchveridze, Evguenia
    Abdallah, Al-Ola
    Paul, Barry
    Green, Kimberly M.
    Davis, James A.
    Hashmi, Hamza
    BLOOD, 2024, 144 : 7034 - 7035
  • [45] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Trudel, Suzanne
    Davis, Randy
    Lewis, Nicole M.
    Bakshi, Kalpana K.
    Chopra, Bikramjit
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Eliason, Laurie
    Kremer, Brandon E.
    Stowell, Delia
    Gupta, Ira
    Wu, Frank S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
  • [46] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; CASTOR)
    Mateos, M. M.
    Spencer, A.
    Hungria, V
    Nooka, A. K.
    Estell, J.
    Barreto, W.
    Corradini, P.
    Min, C. K.
    Medvedova, E.
    Thiyagarajah, P.
    Deraedt, W.
    Chiu, C.
    Schecter, J. M.
    Weisel, K.
    HAEMATOLOGICA, 2018, 103 : 30 - 30
  • [47] EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR
    Weisel, K.
    Lentzsch, S.
    Mateos, M. V.
    Hungria, V.
    Munder, M.
    Nooka, A.
    Mark, T.
    Quach, H.
    Scott, E. C.
    Lee, J. -J.
    Sonneveld, P.
    Casneuf, T.
    Chiu, C.
    Qin, X.
    Amin, H.
    Thiyagarajah, P.
    Schecter, J. M.
    Qi, M.
    Spencer, A.
    HAEMATOLOGICA, 2017, 102 : 168 - 169
  • [48] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
    Moustafa, Muhamad Alhaj
    Parrondo, Ricardo
    Abdulazeez, Mays F.
    Roy, Vivek
    Sher, Taimur
    Alegria, Victoria R.
    Warsame, Rahma M.
    Larsen, Jeremy
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Kapoor, Prashant
    Fonseca, Rafael
    Buadi, Francis K.
    Dingli, David
    Hayman, Suzanne R.
    Reeder, Craig B.
    Agrawal, Arshi
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    BLOOD, 2020, 136
  • [49] Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor
    Spencer, Andrew
    Hungria, Vania T. M.
    Mateos, Maria-Victoria
    Nooka, Ajay
    Estell, Jane
    Barreto, Wolney G.
    Corradini, Paolo
    Min, Chang-Ki
    Medvedova, Eva
    Thiyagarajah, Piruntha
    Deraedt, William
    Chiu, Christopher
    Schecter, Jordan
    Weisel, Katja C.
    BLOOD, 2017, 130
  • [50] Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naive Relapsed Refractory Multiple Myeloma Patients
    Ouchveridze, Evguenia
    Singh, Chandandeep
    Atrash, Shebli
    Paul, Barry
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2022, 140 : 7164 - 7165
12345